Multiple Myeloma New Indication: Isatuximab, Carfilzomib, Lenalidomide, Dexamethasone for Untreated High-Risk Multiple Myeloma Ulas D. Bayraktar, MD 2023-09-23
Diffuse Large B Cell Lymphoma New Protocol: Rituximab, Lenalidomide, and Ibrutinib in DLBCL Ulas D. Bayraktar, MD 2023-06-14
Follicular Lymphoma New Protocol: Lenalidomide-Rituximab for Untreated Follicular Lymphoma Ulas D. Bayraktar, MD 2022-09-20